Thyroid cancer cases double in 20 years, report finds

December 14, 2012
Thyroid cancer cases double in 20 years

The number of people diagnosed with thyroid cancer in England has doubled since the early 1990s, according to a new report published by the National Cancer Intelligence Network (NCIN) today (Friday).

Between 1990 and 1994 around 900 people (1.7 per 100,000 people) were diagnosed with every year in England. By 2006-10 this figure increased to 1,950 (3.4 per 100,000 people). But, thanks to effective treatments, survival rate have remained high, at around 90 per cent.

Researchers from the Oxford Cancer Intelligence Unit found that most of this increase has been seen in a particular type of thyroid cancer called papillary cancer. This form of the disease has the best prognosis.

The rise has been linked to increased diagnosis of the disease through better techniques such as ultrasound and fine that can pick up much smaller cancers and possibly a 'real' rise in the number of people developing thyroid cancer.

Mr David Chadwick, consultant endocrine surgeon at Chesterfield Royal Hospital and Chair of the NCIN Thyroid Working Group, said: "The exact reason behind this steep rise in thyroid cancer cases remains unclear. We now have more sensitive so it could be that more cancers are being picked up when patients are being tested for other conditions. And, this could mean that we're detecting and treating some cancers that would otherwise not have shown up during a person's life.

"We may also be seeing a 'real' increase in the incidence of thyroid cancer, some of which may be due to improved long-term survival of other cancers previously treated with to the neck or chest. Sadly, older forms of radiotherapy had a side-effect that increased the risk of other cancers later in life."

The report also showed that thyroid cancer is three times more common in women than in men. For men and women one year had increased, by nine per cent for men to 88.3 per cent and by 15 per cent for women to 94.3 per cent.

Unlike most cancers, thyroid cancer is most often picked up in people aged between 20 and 59, particularly for the papillary form of the disease, with those aged 30 and 54 having the highest rates.

Treatment for thyroid cancer most commonly includes surgery to remove the thyroid and is often followed up with radioactive iodine. This acts as a 'targeted treatment' as the iodine is only taken up by thyroid cancer cells, ultimately killing them.

While this treatment approach has meant that most people with thyroid cancer are successfully treated, there are some forms of the disease that have a very poor .

Currently, it is difficult for doctors to predict the behaviour of thyroid cancer in an individual patient, which means that most patients will require thyroid surgery.

Chris Carrigan, head of the National Cancer Intelligence Network (NCIN), said: "This increase in the number of people being diagnosed with thyroid cancer reflects a trend that we're seeing in other countries. While thyroid cancer is generally a very treatable disease, there is a lot we don't understand about it. We need to better understand the different forms of the disease so that doctors can predict which patients need more aggressive treatment and which don't."

Explore further: The Medical Minute: Thyroid cancer on the rise

Related Stories

The Medical Minute: Thyroid cancer on the rise

September 21, 2012
September is Thyroid Cancer Awareness Month. With cases on the rise locally, nationally and globally, Dr. David Goldenberg, director of Head and Neck Surgery at Penn State Hershey Medical Center, hopes people will become ...

Have no fear: Most cases of thyroid cancer do not affect survival

June 11, 2012
Research presented at the Society of Nuclear Medicine's 59th Annual Meeting reveals that patients with differentiated thyroid cancer live as long as people in perfect health, unless they are in the minority and have reached ...

BRAF addiction of thyroid cancers makes them therapeutically vulnerable

November 21, 2011
Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly ...

Thyroid cancer treatment varies by hospital, study finds

August 16, 2011
Where thyroid cancer patients go for care plays a large role in whether they receive radioactive iodine treatment, a new study from the University of Michigan Comprehensive Cancer Center finds.

Recommended for you

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.